Medium doses of daily vitamin D decrease falls and higher doses of daily vitamin D3 increase falls: A randomized clinical trial.

What Was Tested

The paper reports a study of Vitamin D, K2, Magnesium and Zinc, published as a randomized controlled trial.

Falls are a serious health problem in the aging population.

The researchers conducted a study of the effect of vitamin D on serum 25 hydroxyvitamin D (25OHD) and data on falls was collected as a secondary outcome.

Who Took Part

By PubMed's age tags, the people studied were middle-aged adults and older adults, women only.

How the Study Was Run

In design terms this was a randomized, double-blind and placebo-controlled study.

Because people in this Vitamin D, K2, Magnesium and Zinc study were split into groups at random, differences between the groups are less likely to reflect who happened to join each one.

Neither the participants nor the staff measuring them knew who was on Vitamin D, K2, Magnesium and Zinc, so expectations could not easily colour the readings.

Some participants received a placebo instead of Vitamin D, K2, Magnesium and Zinc, giving a reference point.

What Was Measured

The researchers conducted a study of the effect of vitamin D on serum 25 hydroxyvitamin D (25OHD) and data on falls was collected as a secondary outcome.

PubMed files the paper under topics including Accidental Falls, Cholecalciferol, Dietary Supplements, Vitamin D, Vitamin D Deficiency and Vitamins.

The authors tagged it with the keywords Clinical trial and Vitamin D supplementation.

What This Means in Plain Language

The paper is a randomized, double-blind and placebo-controlled study of Vitamin D, K2, Magnesium and Zinc.

The publication is from 2017 (The Journal of steroid biochemistry and molecular biology), a journal based in England.

More context: the Vitamin D, K2, Magnesium and Zinc compound page, all human trials.